New Study on Asthma Treatment for Children

A new and significant study has shown that using a dual-action inhaler containing budesonide and formoterol as a standalone treatment to relieve asthma symptoms in children is more effective than salbutamol, the currently common treatment. The study, conducted on children aged 5 to 15, demonstrated that the new device reduces asthma attacks by an average of 45% compared to salbutamol.

Introduction to Childhood Asthma

Asthma is a chronic disease affecting the respiratory system and is one of the most common diseases among children. Asthma attacks can be severe and life-threatening, making it a public health priority to reduce their frequency and severity.

Until now, salbutamol has been the primary treatment for relieving asthma symptoms in children, while adults were recommended to use inhalers containing budesonide and formoterol due to their effectiveness in reducing attacks.

Study Details and Results

The study was led by the Medical Research Institute in New Zealand in collaboration with several international universities and hospitals. A total of 360 children from New Zealand were randomly assigned to receive either budesonide-formoterol or salbutamol for relief as needed. The trial lasted for one year and found that the dual-action inhaler reduced the rate of asthma attacks more significantly than salbutamol, with rates of 0.23 versus 0.41 per participant annually.

The study also confirmed the safety of using the dual-action device, as no significant differences were observed in children’s growth, lung function, or asthma control between the two groups.

Global Impact of the Study

The results suggest the possibility of changing global standards for treating childhood asthma to align with those used for adults, potentially benefiting millions of children worldwide with mild to moderate asthma. Researchers found that incorporating the study’s results into global asthma treatment strategies could help reduce care gaps and ensure children have access to effective, evidence-based treatments.

Researchers noted that global health organizations have long supported targeted interventions for children with asthma, and the study’s results provide crucial evidence to support these efforts.

Conclusion

The study demonstrated that the dual-action inhaler combining budesonide and formoterol could be an effective and safe alternative to traditional inhalers like salbutamol for treating asthma in children. These findings suggest the potential to improve asthma outcomes and reduce the disease burden on children and their families worldwide. As research continues, these results could lead to significant changes in how childhood asthma is managed globally.